Overview
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Status:
Completed
Completed
Trial end date:
2017-06-01
2017-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Criteria
Inclusion Criteria:- Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka
Exclusion Criteria:
- Subjects who have an atopic dermatitis or contact dermatitis flare-up defined as a
sudden intensification of atopic dermatitis.
- Subjects who have an active viral skin infection.
- Subjects with a current or history of malignancy.